Conflict of interest The authors confirm that they have no conflict of interest in connection with this manuscript. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial
License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. see more 2004;63:1538–43.PubMedCentralPubMedCrossRef 2. Burmester G, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–24.PubMedCentralPubMedCrossRef 3. Rajakulendran S, Gadsby K, Allen D, et al. Neutropenia while
receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678–9.PubMedCentralPubMedCrossRef https://www.selleckchem.com/products/acy-738.html 4. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.PubMedCrossRef 5. Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62:764–9.CrossRef
6. Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312–23.PubMedCrossRef 7. Vidal F, Fontova R, Richart C1GALT1 C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003;139:E238–9.CrossRef 8. Furst DE, Kay J, Wasko MC, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013;52:1845–55.CrossRef 9. US FDA. Safety update on TNF-α antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf. 10. Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheum. 2005;23:247–50. 11. Quartier P, Taupinv P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.PubMedCrossRef 12. Menon Y, Cucurulli E, Espinoza LR. Pancytopenia in a signaling pathway patient with scleroderma treated with infliximab. Rheumatology. 2003;42:1273–4.PubMedCrossRef 13. Kuruvilla J, Leitch HA, Vickars L, et al.